Merck cancer drugs and Sanofi, Amgen cardio meds have formularies on high alert

Eric Palmer

U.S. drug payers have been able to beat back prices for some COPD and diabetes , much to the chagrin of GlaxoSmithKline and . But several new categories promise to break out in a big way, and we are not talking just about hepatitis C drugs.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS